Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Third Wave's CF Genotyping Test

NEW YORK (GenomeWeb News) - Third Wave Technologies today said that the US Food and Drug Administration has cleared its InPlex cystic fibrosis genotyping test.
The InPlex CF Molecular Test is based on Third Wave's Invader chemistry and a microfluidic card developed in collaboration with 3M.
The company said that in studies submitted to the FDA as part of its clearance application, the test achieved 100 percent agreement on cystic-fibrosis positive samples and 99.96 overall agreement when compared to DNA sequencing.
Third Wave said the test can be used in carrier screening for adults, as an aid in newborn screening for cystic fibrosis, and in confirmatory diagnostic testing for cystic fibrosis in newborns and children.
Kevin Conroy, president and chief executive of Third Wave, said in a statement that around 70 labs are currently using the company’s InPlex analyte specific reagents for CF testing.
Conroy said that FDA clearance for the test will enable the company to expand its presence in the cystic fibrosis market. He estimated that Third Wave currently holds around 15 percent of that market.
Earlier this week, Third Wave submitted its human papillomavirus test to the FDA for approval.  

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.